Orkambi Coupon Discount


Generic Name: Lumacaftor and Ivacaftor

Bring this coupon to the pharmacy to get a discount on Orkambi. This coupon is 100% free and can be used to get discounts on all your prescriptions. Get coupon discounts at CVS, Walgreens, Walmart, Kroger, Albertsons, Rite Aid, Target, Safeway, and 69,000 drug stores locations!

prescription discount coupon card

Discount Coupon

NEVER EXPIRES

couponprescription.com

Orkambi Coupon

Show this card at a participating pharmacy to receive your discount. For processing questions call Pharmacy support line.

THIS IS NOT INSURANCE

Member ID:

GROUP #:

BIN:

PCN: HT

Pharmacy Support:

Download
Orkambi Coupon

FAQs about Orkambi Coupon

To obtain a discount on your Orkambi prescription, simply present this coupon to the pharmacist during checkout. The process is effortless with Coupon Prescription, making it the most convenient solution for saving money on your prescription medications.

Our coupons and discounts are generally accepted at most pharmacies; however, there may be instances where specific pharmacies cannot apply the coupon code or discount for Orkambi. Despite this, we encourage you to try using our coupons as they come with no cost to download, print, or display on your phone. You stand to gain potential savings!

This Orkambi coupon discount doesn't act as insurance. Sometimes the coupon offers even larger discounts than insurance. The coupon carries no risk - it's always worth asking the pharmacy about potential price reductions when using the coupon.

Just download the coupon, print the coupon or flash your phone to the pharmacists and ask if the price is cheaper for your Orkambi prescription.

The information below is a summary of publicly available data, it should be considered outdated, unreliable, or straight up wrong. This website does not provide medical advice, everything on this website is for informational purposes only. Always consult a medical professional for accurate information about this drug.

Drug Information on Orkambi (Lumacaftor and Ivacaftor)

The active ingredients in ORKAMBI tablets are lumacaftor and ivacaftor. Lumacaftor has the chemical name 3-[6-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3-methylpyridin-2-yl]benzoic acid, with the molecular formula C24H18F2N2O5 and molecular weight of 452.41. Ivacaftor is a CFTR potentiator with the chemical name N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide, with the molecular formula C24H28N2O3 and molecular weight of 392.49. Lumacaftor is a white to off-white powder that is practically insoluble in water. Ivacaftor is also a white to off-white powder that is practically insoluble in water. ORKAMBI tablets are available as pink, oval-shaped, film-coated tablets for oral administration. Each tablet contains 200 mg of lumacaftor and 125 mg of ivacaftor. The tablets also contain inactive ingredients such as cellulose, microcrystalline; croscarmellose sodium; hypromellose acetate succinate; magnesium stearate; povidone; and sodium lauryl sulfate. The tablet film coat contains carmine, FD&C Blue #1, FD&C Blue #2, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac. ORKAMBI is also available as white to off-white granules for oral administration, contained in a unit-dose packet. Each packet contains lumacaftor and ivacaftor in different concentrations. The granules also contain inactive ingredients such as cellulose, microcrystalline; croscarmellose sodium; hypromellose acetate succinate; povidone; and sodium lauryl sulfate.

Usage for Orkambi (Lumacaftor and Ivacaftor)

ORKAMBI is a medication used to treat Cystic Fibrosis (CF) in patients aged 1 year and older who have the F508del mutation in the CFTR gene. It is a combination of ivacaftor and lumacaftor. It is important to use an FDA-cleared CF mutation test to confirm the presence of the F508del mutation before using ORKAMBI. The effectiveness and safety of ORKAMBI have not been studied in patients with CF who do not have the F508del mutation.